Observational Study of Clinical Practice in Patients with Pancreatic Adenocarcinoma in Greece

Figure 3

Progression-free (a) and overall survival (b) of patients according to the sequence chemotherapy regimens as first- and second-line treatments. Sequence 1 (N = 22): nab-paclitaxel/gemcitabine as first-line, followed by FOLFIRINOX/XELOXIRI as second-line treatment. Sequence 2 (N = 19): nab-paclitaxel/gemcitabine as first-line, followed by FOLFOX/CAPOX as second-line treatment. Sequence 3 (N = 14): nab-paclitaxel/gemcitabine as first-line, followed by other regimens as second-line treatment. Sequence 4 (N = 14): FOLFIRINOX/CAPOXIRI as first-line, followed by nab-paclitaxel/gemcitabine as second-line treatment.

(a)

(b)